1. Pristimerin exhibits anti-cancer activity by inducing ER stress and AKT/GSK3β pathway through increasing intracellular ROS production in human esophageal cancer cells.
- Author
-
Hu WB, Liu YT, Li J, Wang Y, Sun XZ, Hua MY, Liu XT, and Hui BN
- Subjects
- Humans, Cell Line, Tumor, Signal Transduction drug effects, Cell Proliferation drug effects, Esophageal Squamous Cell Carcinoma drug therapy, Esophageal Squamous Cell Carcinoma metabolism, Reactive Oxygen Species metabolism, Pentacyclic Triterpenes pharmacology, Esophageal Neoplasms drug therapy, Esophageal Neoplasms metabolism, Proto-Oncogene Proteins c-akt metabolism, Glycogen Synthase Kinase 3 beta metabolism, Endoplasmic Reticulum Stress drug effects, Triterpenes pharmacology, Apoptosis drug effects, Antineoplastic Agents pharmacology, Cell Survival drug effects
- Abstract
Pristimerin (Pris), a bioactive triterpenoid compound extracted from the Celastraceae and Hippocrateaceae families, has been reported to exhibit an anti-cancer property on various cancers. However, the effects of Pris on esophageal cancer are poorly investigated. This current study sought to explore the activity and underlying mechanism of Pris against human esophageal squamous cell carcinoma (ESCC) cells. We demonstrated that Pris showed cytotoxicity in TE-1 and TE-10 ESCC cell lines, and significantly inhibited cell viability in a concentration dependent manner. Pris induced G0/G1 phase arrest and triggered apoptosis. It was also observed that the intracellular ROS level was remarkedly increased by Pris treatment. Besides, the function of Pris mediating the activation of ER stress and the inhibition of AKT/GSK3β signaling pathway in TE-1 and TE-10 cells was further confirmed, which resulted in cell growth inhibition. And moreover, we revealed that all of the above pathways were regulated through ROS generation. In conclusion, our findings suggested that Pris might be considered as a novel natural compound for the developing anti-cancer drug candidate for human esophageal cancer., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF